Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer

Yong Gu Lee(Parker Institute for Cancer Immunotherapy), Marco Ruella(Parker Institute for Cancer Immunotherapy), Ruchi P. Patel(University of Pennsylvania), Nicholas Yang(Parker Institute for Cancer Immunotherapy), Elise A. Chong(Hospital of the University of Pennsylvania), Xueqing Maggie Lu(Parker Institute for Cancer Immunotherapy), Seok Jae Hong(Parker Institute for Cancer Immunotherapy), Hatcher J. Ballard(University of Pennsylvania), Joseph A. Fraietta(University of Pennsylvania), Guido Ghilardi(Hospital of the University of Pennsylvania), Saar Gill(Parker Institute for Cancer Immunotherapy), James N. Gerson(UPMC Hillman Cancer Center), S. Church(Nanostring Technologies (United States)), Kimberly V. Amelsberg(Hospital of the University of Pennsylvania), Simon F. Lacey(University of Pennsylvania), Puneeth Guruprasad(Parker Institute for Cancer Immunotherapy), Sara Cherry(California University of Pennsylvania), Katherine D. Cummins(Parker Institute for Cancer Immunotherapy), Inkook Chun(Parker Institute for Cancer Immunotherapy), Kanupriya Whig(University of Pennsylvania), Patrizia Porazzi(Hospital of the University of Pennsylvania), Wan-Jung Chang(Parker Institute for Cancer Immunotherapy), C Sauter(Parker Institute for Cancer Immunotherapy), D. Schultz(University of Evansville), Khrystyna North(Nanostring Technologies (United States)), Stephen J. Schuster(Hospital of the University of Pennsylvania), Raymone Pajarillo(Hospital of the University of Pennsylvania), Yunlin Zhang(Hospital of the University of Pennsylvania), Jakub Svoboda(UPMC Hillman Cancer Center)
Cancer Discovery
July 29, 2022
Cited by 98


Related Papers